A Case of Acute Myeloid Leukemia after Adalimumab Treatment in Psoriatic Arthritis.

Author: Hong Ki MIN ¹ ; Jae Ho LEE ; Hae Min LEE ; Eunsil KOH ; Ju Yeon HEO ; Jun Ki MIN ; Sung Hwan PARK
Author Information

1. Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul, Korea. rapark@catholic.ac.kr
Publication Type:Case Report
Keywords: Psoriatic arthritis; Acute myeloid leukemia; Adalimumab
MeSH: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia; Leukemia, Myeloid, Acute; Lymphoproliferative Disorders; Receptors, Tumor Necrosis Factor; Spondylarthropathies; Stress, Psychological; Tumor Necrosis Factor-alpha; Adalimumab; Infliximab; Etanercept
From:Journal of Rheumatic Diseases 2012;19(2):91-94
CountryRepublic of Korea
Language:English
Abstract: Hematologic malignancies and lymphoproliferative disorders have been reported after using tumor necrosis factor-alpha inhibitor in patients suffering from spondyloarthropathy. Previously reported cases were treated by using infliximab and etanercept. Usually, it takes approximately several months for leukemia or lymphoproliferative disorders to occur after the application of those agents. However, we report a case of acute myeloid leukemia that developed after short term usage of adalimumab in a patient suffering from psoriatic arthritis.